Viewing 2 reply threads
  • Author
    • #13820
      Jenny Livingston

        Ella Balasa, a columnist at CF News Today, was recently granted early access to the “triple combo” — the latest CFTR modulator therapy from Vertex, which is currently being evaluated by the FDA.

        Here’s what Ella has to say about it:

        “I started the triple combo on September 23rd at 25% lung function. I have been followed at Duke for transplant, but have wanted to hold off on being listed until I gave the triple a shot. After starting, I caught what I thought to be a cold and had increased mucus and sinus draining for about 2 weeks, then it started to reduce in volume.

        I use 3 liters of oxygen when exercising, and my O2 needs have been about the same so I didn’t expect much improvement after 3 weeks. But I had PFTs done and they increased 4% up to 29%! I was shocked, but so happy! I hope to continue seeing improvement as I know I still have mucus plugs in my lungs.”

        Follow Ella’s journey on Instagram at:

        What are your hopes and expectations for the triple combo? 


      • #13825

        Love it! Triple combo is … 😉

      • #13826
        Jenny Livingston

          It’s so exciting! Every time I hear stories like this or see the research (Dr. Boyle’s presentation at BreatheCon was awesome) I get so giddy!

      Viewing 2 reply threads
      • You must be logged in to reply to this topic.

      ©[current-year] KLEO Template a premium and multipurpose theme from Seventh Queen